Double or Nothing Episode #12: ChatGPT, Cortes and the Aztecs

#93: Retail Driving Red-Hot Rally & the $10B Quest for the Holy Grail: Can Grail Change Cancer Detection?

#92: Syntara Phase 2 Success, Geopolitics and Uranium

Episode #66: A crack in the semi facade? Angus Walker joins us

Episode 46: Strategy in the Life Sciences

Episode 41: Where to next? SPACs, rising interest rates and tech stocks

Episode 24: Coronavirus - what's going on? Claude joins us to talk about the impact on specific stocks, and we also cover Afterpay's results

Episode 21: A high-tech company with explosive growth...and various other science things you don't want to miss

Episode 20: Australian bushfires, and two Aussie companies revolutionising burns treatment

Episode 19: How we’re different

Episode 18: Portfolio updates and new ideas with Peter Stevens

Episode 17: Strategy, biotech and growth investing with Eti Amegor

Episode 16: Paul Brennan goes deep on the Australian economy

Episode 15: Growth opportunities and the software sell-off with Peter Stevens

Episode 14: Value is Dead, Long Live Value with Mario Emmanuel

Episode 13: A chat with Anna Satouris about energy, markets and prices

Episode 12: We discuss a strong reporting season and our fee rebate to long term clients

Episode 11: Rebecca Gingell on alloy design and OxMet, an Oxford University spinout

Episode 10: Computing with live neurons - Clinicloud founder takes us through his latest venture

Episode 9: We go deep with Eti Amegor on innovation, disruption and the role of hedge funds in a portfolio